Balipodect

Abandoned PDE10A inhibitor From Wikipedia, the free encyclopedia

Balipodect

Balipodect (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name TAK-063) is a selective phosphodiesterase 10A (PDE10A) inhibitor which was under development by Takeda for the treatment of schizophrenia.[1][2][3]

Quick Facts Clinical data, Other names ...
Balipodect
Thumb
Clinical data
Other namesTAK-063; TAK063
Drug classPhosphodiesterase inhibitor; PDE10A inhibitor; Antipsychotic
Identifiers
  • 1-(2-fluoro-4-pyrazol-1-ylphenyl)-5-methoxy-3-(2-phenylpyrazol-3-yl)pyridazin-4-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H17FN6O2
Molar mass428.427 g·mol−1
3D model (JSmol)
  • COC1=CN(N=C(C1=O)C2=CC=NN2C3=CC=CC=C3)C4=C(C=C(C=C4)N5C=CC=N5)F
  • InChI=1S/C23H17FN6O2/c1-32-21-15-29(19-9-8-17(14-18(19)24)28-13-5-11-25-28)27-22(23(21)31)20-10-12-26-30(20)16-6-3-2-4-7-16/h2-15H,1H3
  • Key:KVHRYLNQDWXAGI-UHFFFAOYSA-N
Close

It is active in animal models of antipsychotic-like activity, including inhibition of hyperlocomotion induced by the NMDA receptor antagonist dizocilpine (MK-801) or the dopamine releasing agent methamphetamine, inhibition of conditioned avoidance responses, and reversal of prepulse inhibition deficits.[4]

The drug reached phase 2 clinical trials for this indication but its development was discontinued.[1][2] It was reported to be poorly effective or ineffective for schizophrenia in clinical trials.[5][6][7]

See also

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.